Further evidence for efalizumab in plaque psoriasis

摘要

Efalizumab,a humanised monoclonal antibody recently approved in the us for treatment of patients with chronic moderate to severs plaque psoriasis has shown further evidence of efficacy.In a phase III double-bined trial,556 patints with moderate to severs plaque psoriasis wee randomly assigned to receive 12 weely doses of subcutaneous efalizumab 1mg/kg or placebo.